Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.

Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Dec 01; 123(23):4566-4573.

View in: PubMed

collapse authors with profiles